Open access · OA
via OpenAlex
TARGETING PRO-INFLAMMATORY CELLS IN IDIOPATHIC PULMONARY FIBROSIS: AN OPEN-LABEL PILOT STUDY OF DASATINIB AND QUERCETIN
Anoop M. Nambiar, Jamie Nicole Justice, Rodolfo M. Pascual, Tamar Tchkonia, Nathan K. LeBrasseur, James L. Kirkland, Nicolas Musi, Stephen B. Kritchevsky
CHEST Journal · 2018 · ▲ 1 citations
Abstract
This 2018 study published in CHEST Journal reports on an open-label pilot trial investigating the use of dasatinib and quercetin in pulmonary fibrosis.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1016/j.chest.2018.08.365
- Canonical
- link ↗
- Fetched
- 2026-10-08 MST
Cite this
APA
Nambiar, A.M., Justice, J.N., Pascual, R.M., Tchkonia, T., LeBrasseur, N.K., Kirkland, J.L., Musi, N., & Kritchevsky, S.B. (2018). TARGETING PRO-INFLAMMATORY CELLS IN IDIOPATHIC PULMONARY FIBROSIS: AN OPEN-LABEL PILOT STUDY OF DASATINIB AND QUERCETIN. <em>CHEST Journal</em>. https://doi.org/10.1016/j.chest.2018.08.365
Vancouver
Nambiar AM, Justice JN, Pascual RM, Tchkonia T, LeBrasseur NK, Kirkland JL, et al. TARGETING PRO-INFLAMMATORY CELLS IN IDIOPATHIC PULMONARY FIBROSIS: AN OPEN-LABEL PILOT STUDY OF DASATINIB AND QUERCETIN. CHEST Journal. 2018. doi:10.1016/j.chest.2018.08.365.
BibTeX
@article{anoop2018TARGET,
title = {TARGETING PRO-INFLAMMATORY CELLS IN IDIOPATHIC PULMONARY FIBROSIS: AN OPEN-LABEL PILOT STUDY OF DASATINIB AND QUERCETIN},
author = {Anoop M. Nambiar and Jamie Nicole Justice and Rodolfo M. Pascual and Tamar Tchkonia and Nathan K. LeBrasseur and James L. Kirkland and Nicolas Musi and Stephen B. Kritchevsky},
journal = {CHEST Journal},
year = {2018},
doi = {10.1016/j.chest.2018.08.365},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
The Lancet 2011
Citation only
Idiopathic pulmonary fibrosis
Cellular Signalling 2019
Citation only
The leading role of epithelial cells in the pathogenesis of idiopathic pulmonary fibrosis
Acta Pharmacologica Sinica 2021
Open access · OA
Roxithromycin attenuates bleomycin-induced pulmonary fibrosis by targeting senescent cells
EBioMedicine 2019
Open access · CC-BY
Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature 2019
Preprint
Faculty Opinions recommendation of Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study.
Current Molecular Biology Reports 2021
Open access · OA